Bellerophon Therapeutics — Technical Presentation (June 2023)
9 slides from Bellerophon Therapeutics's technical presentation, Jun 5, 2023
Slide 1: Conference Call June 5, 2023 Bellerophon Therapeutics
Conference Call I June 5, 2023 Bellerophon Therapeutics
Slide 2: Forward Looking Statements
Bellerophon Therapeutics Overview | June 2023 2 Forward Looking Statements This presentation contains forward - looking statements that involve substantial risks and uncertainties . All statements, other than statements of historical facts, contained in this presentation, including statements regard
Slide 3: Pivotal Phase 3 Trial Design
Bellerophon Therapeutics Overview | June 2023 3 Pivotal Phase 3 Trial Design Open label extension patients continue on iNO45 or switch from placebo to iNO45 Primary Endpoint • Change in MVPA assessed by Actigraphy Additional Endpoints • Change in Overall Activity assessed by Actigraphy • Patient Rep
Slide 4: Demographics were balanced between the arms
Bellerophon Therapeutics Overview | June 2023 4 Demographics were balanced between the arms REBUILD Demographics INO45 Placebo Total Patients • Intermediate/High Probability of PH • Low Probability of PH 75 31 (41.3%) 44 (58.7%) 70 29 (41.4%) 41 (58.6%) Age – Mean (SD) 67.8 (9.5) 68.7 (9.4) Male (%)
Slide 5: Trial did not meet its primary endpoint of change in MVPA
Bellerophon Therapeutics Overview | June 2023 5 Trial did not meet its primary endpoint of change in MVPA (moderate to vigorous physical activity) REBUILD Primary Endpoint (MVPA) Analysis based on all randomized subjects who received at least one dose of study treatment (defined as minimum use of 12
Slide 6: Minimal difference between the two groups
Bellerophon Therapeutics Overview | June 2023 6 Minimal difference between the two groups REBUILD Secondary Endpoints Analysis based on all randomized subjects who received at least one dose of study treatment (defined as minimum use of 12 hou rs) ; Statistical analysis are calculated from MMRM (mix
Slide 7: REBUILD Secondary Endpoints (time to event)
Bellerophon Therapeutics Overview | June 2023 7 REBUILD Secondary Endpoints (time to event) Time to event, defined as first event, otherwise censored to the end date of the double - blind period. Log - Rank p - value is calculated from log rank test comparing INOpulse treatment group to placebo. Tim
Slide 8: Overall Safety profile was balanced
Bellerophon Therapeutics Overview | June 2023 8 Overall Safety profile was balanced REBUILD Safety Assessment Safety analysis based on all subjects who received at least one dose post randomization (defined as exposure to INOpulse of a ny duration) of treatment intervention. TEAE (treatment emergent
Slide 9: Investor Contacts
Investor Contacts Bellerophon Investor Relations BTInvestorRelations@bellerophon.com Brian Ritchie I LifeSci Advisors britchie@lifesciadvisors.com 212 - 915 - 2578
Bellerophon Therapeutics — Technical Presentation (June 2023) on 6ix